Enoxaparin Sodium Injection, 120 MG/0.2 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML
Enoxaparin Sodium Injection, 120 MG/0.2 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML - Image 2
Enoxaparin Sodium Injection, 120 MG/0.2 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML - Image 3
Enoxaparin Sodium Injection, 120 MG/0.2 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML - Image 4
Categories:, SKU: 00014-146
Enoxaparin Sodium Injection, 120 MG/0.2 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML

Download as PDF
Enquire Now

Description

PRODUCT DESCRIPTION:

 

Enoxaparin Sodium Injection is a low molecular weight heparin (LMWH) used extensively in the prevention and treatment of thromboembolic disorders.

With a high affinity for antithrombin III, it works by inhibiting clot formation and is widely used for deep vein thrombosis (DVT), pulmonary embolism (PE), and in acute coronary syndrome (ACS) settings.

Formulated in ready-to-use Pre-Filled Syringes, this product ensures precise dosing, sterility, ease of administration, and superior compliance—ideal for hospital and outpatient care.

Formulation & Presentation:

  • Dosage Form: Sterile Injectable (Sterile Lyophilized Solution for Reconstitution)
  • Presentation: Pre-Filled Syringe (customizable as per market demand)
  • Available Strengths:
    • 40 MG/ 0.2 ML (Pre-Filled Syringe)
    • 60 MG/ 0.4 ML (Pre-Filled Syringe)
    • 80 MG/ 0.6 ML (Pre-Filled Syringe)
    • 120 MG/ 0.8 ML (Pre-Filled Syringe)
  • Route of Administration: Subcutaneous (SC)/ Intravenous (IV-Bolus) for select indications (e.g: STEMI) To be used only in advanced clinical settings, as per clinical indication and severity. To be administered under supervision of a qualified specialist only. (As per physician’s discretion or decision)

Therapeutic Indications:

  • Prophylaxis of DVT in surgical and medical patients
  • Treatment of DVT and PE, with or without PE
  • Prevention of clot formation in extracorporeal circulation during hemodialysis
  • Management of unstable angina and non-Q-wave myocardial infarction
  • ST-elevation myocardial infarction (STEMI) in conjunction with thrombolytics

Side Effects:

  • COMMON:
    • Injection site pain, bruising
    • Mild bleeding
    • Nausea or mild headache
  • SERIOUS (RARE):
    • Severe bleeding or hemorrhage
    • Thrombocytopenia (including HIT)
    • Skin necrosis or allergic reactions
    • Spinal/epidural hematoma (in patients with spinal anesthesia)
  • PRECAUTIONS:
    • Use cautiously in patients with renal impairment or a history of bleeding disorders
    • Monitor platelet count during treatment
    • Avoid concurrent use of NSAIDs or other anticoagulants unless clinically indicated
    • Not to be administered intramuscularly
    • Caution in epidural/spinal anesthesia procedures due to bleeding risk

Reviews

There are no reviews yet.

Be the first to review “Enoxaparin Sodium Injection, 120 MG/0.2 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML”

Your email address will not be published. Required fields are marked *

12345

TECHNICAL INFORMATION

Product Specifications:

  • HSN Code: To be assigned per international classification standards & import jurisdiction
  • Weight: Approx. 40 GM per Carton (With Packaging)
  • Dimensions: (15x1x8 CMS)
  • Shelf Life (Subject To Country Specific Guidelines): 24 to 36 months under recommended storage conditions from date of manufacture or as per label specifications
  • Storage: Store between 2°C to 25°C for Pre-Filled Syringes/Lyophilized (Do not freeze). Does not require cold-chain logistics. Protect from moisture and direct sunlight. The solution should be used strictly as per label guidelines.

Regulatory Status & Supply Information:

  • Regulatory Status: WHO-GMP Complaint Manufacturing. COA, MSDS, Stability Data, Manufacturing Batch Record, Dossier Support (on request). Further certifications available on request
  • Exports Ready Dossiers: COA, COPP, Dossier Available (CTD/eCTD formats). Complies with USP/EP/BP Standards
  • Stability: Compliant
  • MOQ: Negotiable. Based on market & registration status
  • Export Options: Available for private label, institutional supply, or branded export

Who Should Source This Product?

  • Hospitals and emergency care centers requiring high-quality anticoagulants
  • Government health agencies and tenders needing reliable low molecular weight heparins
  • Distributors in LATAM, Africa, and South Asia sourcing specialty injectables
  • NGOs and humanitarian health programs managing DVT, trauma, and cardiovascular care
  • Pharma buyers focused on critical care & surgical support therapies seeking cost-effective yet internationally compliant LMWH products

Why Source from PHARMET?

  • Single-window sourcing for diverse pharma needs
  • Export-ready documentation & regulatory support
  • Adaptable documentation support for effective registration support
  • Trusted consortium network, simplifying India’s complex pharma supply chain
  • Multiple approved manufacturers for best fit in import country
  • Network of audited, compliant manufacturers across India
  • Customizable & Flexible branding, packaging & formulation flexibility
  • End to End Logistics support flexibility & support
  • Deep expertise in exporting specialty injectables & all products

CONTACT DETAILS:

Related items